Dyne Therapeutics, Inc.
DYNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Dyne Therapeutics, Inc. focuses on Biotechnology services and products. Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. With a market capitalization of $4.53B, it sits in mid-cap territory. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Market Cap
$4.53B
Beta
1.08
P/E (TTM)
—
P/E (Fwd)
-7.27
EPS (TTM)
$-3.26
EPS (Fwd)
$-3.34
ROE
-81.6%
ROA
-39.0%
Cash
$898.5M
Total Debt
$233.3M
Free CF
-$317.1M
52W Change
83.3%
Annual Financials
Cash vs Debt
Where DYN stands vs its 150-day and 200-day moving averages
As of the August 12, 2026 close, DYN finished 39.19% above its 150-day moving average ($19.19) and 37.33% above its 200-day moving average ($19.45). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DYN overbought or oversold?
At the August 12, 2026 close, DYN's RSI(14) was 75.8, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $898.5M in cash comfortably exceeding the $233.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$317.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -81.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Dyne Therapeutics, Inc. and its sector.